Drugs & Therapy Perspectives

, Volume 15, Issue 5, pp 12–16 | Cite as

Choosing the best antiretroviral regimen by HIV resistance testing?

Practical Issues and Updates
  • 10 Downloads

Keywords

Human Immunodeficiency Virus Type Omeprazole Zidovudine Misoprostol Adefovir 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Vandamme A-M, Van Laethem K, De Clerq E. Managing resistance to anti-HIV drugs. An important consideration for effective disease management. Drugs 1999 (Mar); S7 (3): 337–61CrossRefGoogle Scholar
  2. 2.
    Jacobsen H, Hänggi M, Ott M, et al. In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies. J Infect Dis 1996; 173: 1379–87PubMedCrossRefGoogle Scholar
  3. 3.
    Schmit J-C, Van Laethem K, Ruiz L, et al. Multiple dideoxynucleoside analogue resistant (MddNR) HIV-I strains isolated from patients from different European countries. AIDS 1998; 12: 2007–15PubMedCrossRefGoogle Scholar
  4. 4.
    Boucher CAB, O’Sullivan E, Mulder JW et al. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis 1992; 165: 105–10PubMedCrossRefGoogle Scholar
  5. 5.
    Sharma PL, Crumpacker CS. Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation. J Virol 1997; 71: 8846–51PubMedGoogle Scholar
  6. 6.
    Larder BA. Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. J Gen Virol 1994; 75: 951–7PubMedCrossRefGoogle Scholar
  7. 7.
    Schinazi RF, Larder BA, Mellors JW. Mutations in retroviral genes associated with drug resistance. Int Antiviral News 1997; 5: 129–42Google Scholar
  8. 8.
    Durant J, Clevenbergh P, Halfon P, et al. Drug resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999 (26 Jun); 353: 2195–99PubMedCrossRefGoogle Scholar
  9. 9.
    Visible Genetics Inc. Twelve-month VIRADAPT clinical data shows HIV genotyping to have potential for positive long-term benefit. Media Release: 24 Jun 1999Google Scholar
  10. 10.
    Little SJ, Daar ES, D’Aquila RT, et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 1999; 282: 1142–9PubMedCrossRefGoogle Scholar
  11. 11.
    Fauci AS, Bartlett JG, Goosby EP, et al. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Ann Intern Med 1999; 128:1079–100Google Scholar

Copyright information

© Adis International Limited 2000

Personalised recommendations